Dominika Suchonova2023-09-01T15:04:14+00:0013-06-2023|
Registration is now open for the virtual event Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden, taking place virtually on 26 September 2023 at 09:00 – 11:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Swedish Brain Foundation (SBF) and the Swedish Association of [...]
Dominika Suchonova2023-09-06T14:44:03+00:0013-06-2023|News|
Save the date for the virtual event Rethinking Alzheimer’s disease: Moving towards a new Alzheimer’s disease detection and diagnosis pathway in Sweden, set to take place on 26 September 2023 at 10:00 – 12:00 (Brussels time)! About Alzheimer’s disease Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase [...]
Dominika Suchonova2023-05-09T14:04:52+00:0020-04-2023|
Walking the Talk for Dementia is an innovative, adventurous and immersive experience involving people working, researching and living with dementia. Dementia is a pressing issue for our lifetime, and society needs to be responsive to ensure that people can live with more dignity and access to services and resources despite their diagnosis. The project's [...]
Dominika Suchonova2023-04-03T14:57:28+00:0014-03-2023|News|
On the occasion of the Brain Awareness Week, the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) launch the RETHINKING Alzheimer's disease White Paper, calling for change in the detection and diagnosis of Alzheimer's disease. About Alzheimer's disease Alzheimer’s disease (AD), the most common form of [...]
Dominika Suchonova2023-03-30T09:01:01+00:0024-01-2023|News|
Every three seconds someone develops dementia and for most of these individuals this will be as a result of Alzheimer’s disease, the leading cause. Alzheimer's is a relentless neurodegenerative condition which robs people of their memories, their independence, their relationships, and ultimately, their lives. On 24 January 2023, the European Brain Council (EBC), in collaboration [...]
Dominika Suchonova2023-01-10T12:03:16+00:0008-12-2022|News|
Registration is now open for the launch event of the RETHINKING Alzheimer's disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper [...]
Dominika Suchonova2023-01-10T13:12:36+00:0024-11-2022|News|
The launch event of the RETHINKING Alzheimer's disease White Paper, calling for change in Alzheimer's care, will take place virtually on 24 January 2023 at 12:30 - 14:00. About Alzheimer's disease Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause [...]
Dominika Suchonova2023-01-11T08:46:20+00:0010-11-2022|
The launch event of the RETHINKING Alzheimer’s disease White Paper, calling for change in Alzheimer’s care, will take place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper is [...]
Dominika Suchonova2023-02-06T12:34:26+00:0026-10-2022|News|
Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health needs. It represents between 60% and 70% of the dementia cases. It is still diagnosed too late when the symptoms become evident as the disease progresses. AD is now portrayed as continuum consisting of 3 stages: [...]
Dominika Suchonova2023-02-24T10:57:04+00:0016-09-2022|
Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health and health systems‘ needs. AD represents between 60 and%70% of the dementia cases. It is still diagnosed too late, when the symptoms become more evident as the disease progresses. AD is now portrayed as a continuum [...]
